September 3, 2009 – On Tuesday, Aug. 11, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure.

The FoxCross PTA Catheter is a next-generation .035 balloon dilatation catheter is used to open peripheral arteries that have become blocked with plaque. The system is available in a wide variety of diameters (3-14 mm), balloon lengths (20-120 mm), and catheter lengths (50 cm, 80 cm and 135 cm) on an over-the-wire delivery platform.

September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).

September 2, 2009 – Edwards Lifesciences Corp. said this week it completed enrollment in its 1,040-patient randomized controlled investigational device exemption (IDE) study of the Edwards SAPIEN transcatheter heart valve.

September 3, 2009 – Boston Scientific Corp. said Tuesday long-term data from the Prevention of Sudden Cardiac Death II registry (PreSCD II) found that implantable cardioverter defibrillators (ICDs) were associated with a 44 percent reduction in all cause mortality when implanted in patients following myocardial infarction.

September 3, 2009 – The OASIS study group presented initial results of the CURRENT-OASIS 7 clinical trial Sunday at the European Society of Cardiology Congress in Barcelona, which did not show a statistical difference between the high-dose and standard-dose PLAVIX regimens, but subgroups did show some improvement.

September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.

September 2, 2009 – Volcano Corp. said this week it entered into a nonexclusive, global resale agreement with Siemens Healthcare where Siemens will resell Volcano’s s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray systems.

September 2, 2009 – A new analysis from the JUPITER study showed CRESTOR (rosuvastatin calcium) 20 mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39 percent, compared to placebo, in elderly patients with LDL-C less than 130 mg/dL and elevat

September 1, 2009 - Evaluation of results of a multicenter study indicates that quantitative evaluation of the progression of volume of extracranial carotid vessel walls is feasible with 1.5T magnetic resonance (MR) imaging, despite limitations due to patient motion or habitus.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now